Search

Summary This Good Practice Paper provides recommendations for the diagnosis and initial management of transplant‐eligible high‐risk myeloma patients. It describes recent updates to the genetic diagnostics of high‐risk myeloma and provides recommendations for treatment on the basis of recent prospective clinical trial evidence. [ABSTRACT FROM AUTHOR]

This article provides information on the diagnosis and management of smouldering myeloma, a precursor condition to multiple myeloma. It discusses various diagnostic tests and imaging techniques used to identify smouldering myeloma and emphasizes the importance of restaging if there is evidence of progression. The article also provides recommendations for screening and initial investigations for suspected myeloma. Additionally, it discusses risk stratification models and treatment options for smouldering myeloma, including the use of lenalidomide. The article concludes by highlighting ongoing clinical trials and the need for further research in the treatment of smouldering myeloma. [Extracted from the article]

Summary: This Good Practice Paper provides recommendations for the diagnosis, risk stratification and management of the monoclonal gammopathy of undetermined significance (MGUS). It describes the recently recognised entity of the monoclonal gammopathy of clinical significance (MGCS), and recommends how it should be managed. The potential for targeted population screening for MGUS is also discussed. [ABSTRACT FROM AUTHOR]

EVALUATION OF ABILITY TO TOLERATE THERAPY (COMORBIDITY ASSESSMENT AND MORTALITY PREDICTION) Evaluation of fitness for treatment in older AML patients All patients should be assessed for their suitability to receive intensive induction therapy at presentation. CLINICAL TRIALS This patient population has historically contributed low recruitment to clinical trials due to ineffective therapies, adverse disease biology and physical limitations of the older AML patient. High risk, fit, older patients with high-risk APL (white cell count >10 × 10 SP 9 sp /L) can be treated with a similar treatment approach to that used in younger patients, although dose reduction should be considered with chemotherapy (especially anthracyclines)-based regimens.97-100 Patients with a high white cell count >10 × 10 SP 9 sp /L should receive prophylactic corticosteroids which can potentially reduce the risk of APL differentiation syndrome.97,99 Dexamethasone 10 mg intravenously twice a day should be started immediately at the earliest clinical suspicion of APL differentiation syndrome. An evaluation of 17 years of low dose cytarabine as therapy for AML patients not fit for intensive treatment, including patients with adverse cytogenetics, shows improving survival, potential underutilisation and highlights the need for new therapy. An analysis of 2,767 AML patients in the Swedish Acute Leukaemia Registry evaluated the effect of the decision to treat on outcomes.31 In this study, 30-day mortality rates were dependent on both age and PS; however, older patients with good PS had low early death rates and patients with poor PS had increased early mortality across all ages. [Extracted from the article]

The presence of multiple bleeding symptoms and/or severe bleeding symptom(s) contribute to a higher score and therefore a greater chance of a bleeding disorder diagnosis. There is bleeding at a critical site (e.g., ICH, retinal haemorrhage, gastrointestinal haemorrhage, intraspinal haemorrhage, haemarthrosis) with no correlating history of trauma or other explanation that adequately accounts for the bleeding. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. A standardised bleeding assessment tool, e.g., the International Society for Haemostasis and Thrombosis Bleeding Assessment Tool (ISTH-BAT), can be used to quantitate bleeding symptoms in order to generate a bleeding score. [Extracted from the article]

Firstly, much of globin gene testing required for pre- and neonatal diagnosis requires a rapid turnaround time and analysis of a small number of genes, making it unwieldy and unnecessary to be testing all of the genes on a panel. Diamond-Blackfan anaemiaADRPL111p36.11Ribosomal protein L11NM 000975.5Diamond-Blackfan anaemia 7ADRPL153p24.2Ribosomal protein L15NM 002948.5? Globin gene variants are the commonest cause of inherited anaemia, and all patients should be formally assessed for their presence, using a combination of haemoglobin analysis and specific genetic tests for suspected variants, and by inclusion on NGS panels, depending on local practice. Finally, NGS-based genetic testing is useful for the identification of complex modes of inheritance that are recognised to account for at least 4% of diagnosed Mendelian conditions.20 Recommendations NGS should only be used in cases where acquired causes are thought to be very unlikely (IA) Appropriate consent should be obtained (IA) Globin gene abnormalities should be considered and investigated appropriately before NGS is carried out, including haemoglobin analysis and sequencing of individual globin genes, depending on the genetic distribution that is already known in the local population. [Extracted from the article]

Summary: A consensus statement for the management for patients of all ages with all stages of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) — All StAGEs — is proposed by representatives of the UK National Cancer Research Institute (NCRI) Hodgkin lymphoma study group and the Children's Cancer & Leukaemia Group. Based on current practices and published evidence, a consensus has been reached regarding diagnosis, staging and risk‐ik7 stratified management which includes active surveillance, low‐ and standard‐dose immunochemotherapy and radiotherapy. [ABSTRACT FROM AUTHOR]

RT occurs in 2-10% of CLL patients, usually during the disease course rather than at presentation, representing a transformation rate of 0-5-1% per CLL patient per year.2-5 RT should be suspected when a CLL patient develops one or more new "B symptoms", asymmetric, rapidly progressive lymphadenopathy, or a sudden lactate dehydrogenase (LDH) rise. Treatment approach Patients with RT commonly present in the context of pre-treated CLL and immunosuppression, and given the typical demographics of the CLL population, patients are often older with co-existing comorbidities.22 Treatment has historically involved multi-agent cytotoxic chemotherapy, more recently in combination with an anti-CD20 monoclonal antibody. Patients with I TP53 i aberrations or those who develop RT having previously received CLL-directed treatment have a poor outcome with R-CHOP alone, although this remains the standard of care and provides at least initial disease control for most patients. Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. [Extracted from the article]

• Equivocal or borderline CMV IgG values in patients transfused with CMV-U components may indicate passive rather than immune acquisition of IgG and should prompt a repeat confirmatory test (Grade 1C). CMV IgG, CMV IgM and CMV polymerase chain reaction (PCR) may help in distinguishing passive transfer from actively acquired antibody. The British Society for Haematology (BSH) produces Good-Practice Papers to recommend good practice in areas where there is a limited evidence base but for which a degree of consensus or uniformity is likely to be beneficial to patient care. [Extracted from the article]

Summary: The International Collaboration for Transfusion Medicine Guidelines (ICTMG) has published guidance on transfusion for haemoglobinopathies. To give a UK perspective on this guidance, each of the recommendations in the ICTMG guideline were reviewed and the applicability for transfusion practice in the UK considered with reference to relevant published British Society for Haematology (BSH) guidelines and national standards. There was much consensus; however, there was disparity surrounding the recommendations for routinely extended matching in those with alloimmunisation. [ABSTRACT FROM AUTHOR]

The article focuses on the Good Practice Paper compiled by the British Society for Haematology (BSH) consisting of evidence regarding the management of primary mediastinal B‐cell lymphoma (PMBCL). It talks about the gene expression and the pathogenesis of PMBCL along with the impact of nuclear Factor-kB (NF-kB) pathways on the patient.

The article focuses on the glucocorticoids being a risk factor causing osteoporosis in patients with immune thrombocytopenia (ITP) receiving steroids. It talks about the Good Practice Paper compiled by the British Society for Haematology (BSH) consisting of guideline for the prevention of glucocorticoid-induced osteoporosis (GIO) during the treatment of patients with ITP.

The article discusses the diagnosis and investigation of patients with mantle cell lymphoma (MCL. Topics covered include the latest information on molecular pathology, the use of positron emission tomography/computed tomography (PET/CT) scanning in staging and response assessment, and biological prognostic factors of MCL.

Summary: Immune thrombocytopenia (ITP) resolves in most children within 3–12 months of diagnosis. Chronic ITP affects 10%–20% of patients, some of whom require treatment. Several second‐line agents are efficacious in this group of patients. This paper describes our experience of using dapsone as a single second‐line agent in children with chronic ITP. One hundred and three children with chronic ITP were seen at our centre from January 2012 to December 2016. Forty‐five children met the inclusion criteria and received dapsone; 17 (37.8%) were boys; and 28 (62.2%) were girls. Early response to dapsone was seen in 37.8% of patients. The median duration of long‐term follow‐up was 50 months, and at least a partial response was seen in 64.4% of the patients. Dapsone offers good initial response rates and sustained remission in paediatric chronic ITP, comparable to other therapeutic agents available. [ABSTRACT FROM AUTHOR]

ABO‐non‐identical (ni) platelets provide less of an increase in platelet count and may increase the length of patient transfusions. The paper by Han and Badami showed that ABO‐ni platelets may be a risk factor for immune platelet transfusion refractoriness. Commentary on: Han et al. ABO non‐identical platelet transfusions, immune platelet refractoriness and platelet support. Br J Haematol 2024;204:2097‐2102. [ABSTRACT FROM AUTHOR]

Summary: For this paper, cases reported formally and anecdotally to the authors in their screening and diagnostic roles have been selected to demonstrate areas where errors have occurred, and caution should be exercised. The cases demonstrate that it is vital that the performance and limitations of the techniques used, along with the phenotypic presentation of cases where haemoglobin variants and/or thalassaemias are coinherited are understood by those performing result interpretation. Those who deliver the service as well as those who receive reports and give results and counselling should be aware of the complexity of the topic. [ABSTRACT FROM AUTHOR]

Summary: Since the publication in 2017 of the revised 4th Edition of the World Health Organization (WHO) classification of haematolymphoid tumours, here referred to as WHO‐HAEM4, significant clinicopathological, immunophenotypic and molecular advances have been made in the field of lymphomas, contributing to refining the diagnostic criteria of several diseases, upgrading entities previously defined as provisional and identifying new entities. This process has resulted in two recent classification proposals of lymphoid neoplasms: the International Consensus Classification (ICC) and the 5th edition of the WHO classification (WHO‐HAEM5). In this paper, we review and compare the two classifications in terms of diagnostic criteria and entity definition, focusing on T‐cell lymphomas and histiocytic/dendritic cell tumours. Moreover, we update the genetic data of the various pathological entities. The main goal is to provide a tool to facilitate the work of the pathologists, haematologists and researchers involved in the diagnosis and treatment of these haematological malignancies. [ABSTRACT FROM AUTHOR]

Recent clinical studies demonstrated the achievement of lymphoma responses in patients with Hepatitis C virus‐associated indolent lymphoproliferative disorders (LPD) receiving direct‐acting antivirals (DAAs) as their sole treatment. However, the molecular mechanisms underlying LPD responses to DAAs are still poorly understood. In their paper the authors provide new molecular insights on this issue, reporting intraclonal diversification and persistence of B‐cell clones in most cases, despite viral eradication and beneficial clinical outcome. These provocative data suggest that the achievement of molecular response is probably not required for a 'functional cure' of these patients. Further comprehensive immunogenetic and mutational studies would be fundamental to dissect this biological puzzle and, ultimately, to refine improved treatment strategies in this setting. Commentary on: Mazzaro et al. Persistence of monoclonal B‐cell expansion and intraclonal diversification despite virus eradication in patients affected by hepatitis C virus‐associated lymphoproliferative disorders. Br J Haematol 2023;203:237‐243. [ABSTRACT FROM AUTHOR]

Summary: A subset of individuals with 'primary' or 'idiopathic' immune thrombocytopenia (ITP) who fail to respond to conventional first‐ and second‐line agents or who lose responsiveness are considered to have 'refractory' disease (rITP), placing them at increased risk of bleeding and complications of intensive treatment. However, the criteria used to define the refractory state vary among studies, which complicates research and clinical investigation. Moreover, it is unclear whether rITP is simply 'more severe' ITP, or if there are specific pathogenic pathways that are more likely to result in refractory disease, and whether the presence or development of rITP can be established or anticipated based on these differences. This paper reviews potential biological features that may be associated with rITP, including genetic and epigenetic risk factors, dysregulation of T cells and cytokine networks, antibody affinity and specificity, activation of complement, impaired platelet production and alterations in platelet viability and clearance. These findings indicate the need for longitudinal studies using novel clinically available methodologies to identify and monitor pathogenic T cells, platelet antibodies and other clues to the development of refractory disease. [ABSTRACT FROM AUTHOR]

Summary: Since its first description by Evans in 1951, this syndrome has been linked to chronic immune thrombocytopenia with the concurrent or delayed onset of autoimmune haemolytic anaemia or neutropenia. For decades, the evolution of Evans syndrome (ES) has carried a poor prognosis and often resulted in chronic steroid exposure, multiple immune suppressing medications directed against T or B lymphocytes, and splenectomy. This paper presents a new view of ES based on recent advances in genomics which begin to classify patients based on their underlying molecular variants in previously described primary immune disorders. This has opened up new avenues of targeted therapy or bone marrow transplant at rather than broad long‐term immune suppression or splenectomy. Importantly, recent studies of the full lifespan of ES suggest that at least 80% of those paediatric patients will progress to various clinical or biological immunopathological manifestations with age despite the resolution of their cytopenias. Those patients merit long‐term follow‐up and monitoring in dedicated transition programs to improve outcome at the adult age. [ABSTRACT FROM AUTHOR]

Summary: Primary immune thrombocytopenia (ITP) is an autoimmune disorder characterized by isolated thrombocytopenia. This bibliometric analysis was applied to identify the characteristics of global scientific output, the hotspots, and frontiers of ITP over the past 10 years. We retrieved publications from 2011 to 2021 from the Web of Science Core Collection (WoSCC). Bibliometrix package, VOSviewer, and Citespace were used to analyse and visualize the trend, distribution, and hotspots of research on ITP. Altogether, there were 2084 papers, written by 9080 authors from 410 organizations in 70 countries/regions, published in 456 journals with 37 160 co‐cited references. In the last decades, the most productive journal was British Journal of Haematology, China was the most productive country. and the most cited journal was Blood. Shandong University was the most productive institution in the field of ITP. NEUNERT C, 2011, BLOOD, CHENG G, 2011, LANCET, and PATEL VL, 2012, BLOOD were the top three most cited documents. "Thrombopoietin receptor agonist", "regulatory T cell" and "sialic acid" were three hotspots of the last decade. And "immature platelet fraction", "Th17", and "fostamatinib" would be research frontiers in the feature. The present study provided a novel insight for future research directions and scientific decision‐making. [ABSTRACT FROM AUTHOR]

In their paper, the authors present their experience with the use of chimeric antigen receptor T cells targeting CD7 as a bridge to allogeneic haematopoietic cell transplantation in patients with relapsed/refractory T‐cell acute lymphoblastic leukaemia/lymphoblastic lymphoma. Commentary on: Cao et al. A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T‐cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complete remission after autologous CD7 chimeric antigen receptor T‐cell therapy. Br J Haematol 2024;204:2351‐2364. [ABSTRACT FROM AUTHOR]

In their paper, the authors quantified liver iron concentration (LIC) and hepatic steatosis (HS) using MRI‐T2* technology in transfusion‐dependent thalassaemia (TDT) patients and healthy controls and found that the prevalence of HS among patients with TDT was 36.4%. In comparison with healthy controls, the hepatic fat fraction (FF) was significantly higher in the TDT population (p = 0.013). Active hepatitis C virus infection, body mass index (BMI) and LIC were independent predictors of HS. An inverse correlation between hepatic FF and high‐density lipoprotein cholesterol (p = 0.042) and a significant association of high glycaemia level (p = 0.037) with higher hepatic FF and a significant relationship (p = 0.026) between HS and higher BMI (though in a ‘lean’ group of patients) in TDT patients indicated that ‘metabolic syndrome’ was present in this subset with TDT. The impact of metabolic syndrome on TDT, including cardiac disease unrelated to iron overload, needs further study.Commentary on: Ricchi et al. Liver steatosis in patients with transfusion‐dependent thalassaemia. Br J Haematol 2024 (Online ahead of print). doi: 10.1111/bjh.19496. [ABSTRACT FROM AUTHOR]

The rich history surrounding Diamond–Blackfan anaemia (DBA), originally described in 1938 as congenital hypoplastic anaemia2 reflects the evolution of paediatric haematology. In their paper, the authors1 present the results of a clinical trial using the thrombopoietin‐mimetic agent eltrombopag to treat red cell failure in DBA. A low response rate belies the importance of this work. Commentary on: Duncan et al. Treatment of refractory/relapsed Diamond–Blackfan anaemia with eltrombopag. Br J Haematol 2024;204:2077‐2085. [ABSTRACT FROM AUTHOR]

Up‐front allogeneic haematopoietic stem cell transplantation (allo‐HSCT) after a reduced intensity conditioning regimen is the standard treatment in children with acquired severe aplastic anaemia (aSAA) and inherited bone marrow failure syndromes (iBMFs) in the presence of a healthy matched related donor (MRD). The paper by Alsultan et al. report the safety and efficacy of MRD HSCT conditioned with low‐dose cyclophosphamide, fludarabine and thymoglobulin in both aSAA and non‐Fanconi iBMFs, strengthening the concept of the pivotal role of immunosuppressive approach in allo‐HSCT for specific subgroups of non‐malignant diseases requiring a reduced risk of toxicities, offering the opportunity to discuss the essential points for achieving patients' long‐term survival after MRD HSCT in BMF. Commentary on: Alsultan et al. Human leucocyte antigen‐matched related haematopoietic stem cell transplantation using low‐dose cyclophosphamide, fludarabine and thymoglobulin in children with severe aplastic anaemia. Br J Haematol 2023;203:255‐263. [ABSTRACT FROM AUTHOR]

The new 2022 WHO classification has replaced the category of AML with myelodysplasia-related changes (AML-MRC) with AML-Myelodysplasia Related (AML-MR) and its diagnostic criteria are updated (see Endnote). Keywords: cytogenetics; flow cytometry; leukaemia diagnosis; molecular genetics; myeloid leukaemia EN cytogenetics flow cytometry leukaemia diagnosis molecular genetics myeloid leukaemia 150 159 10 01/16/23 20230115 NES 230115 METHODOLOGY This Good Practice Paper was compiled according to the BSH process (https://b-s-h.org.uk/media/19922/bsh-guidance-development-process-july-2021.pdf). Key changes include removal of morphology alone to make a diagnosis of AML-MR, updating the cytogenetic criteria and introducing the mutation-based diagnosis of AML-MR. INTRODUCTION Making a diagnosis of acute myeloid leukaemia (AML) requires a multi-faceted approach bringing together clinical features of patient presentation with laboratory investigations encompassing morphological, immunophenotypic and genetic evaluation of blood, bone marrow and, when appropriate, cerebrospinal fluid (CSF). [Extracted from the article]

The article focuses on papers to be published in future issues of the "British Journal of Haematology" on topics such as pulmonary embolism diagnosis in pregnancy, race-based differences in the cytogenetic profiles of multiple myeloma patients, and mutations in pediatric acute myeloid leukemia.

The research papers to be published in upcoming issues of the "British Journal of Haematology" is presented which include "Treatment rates of pediatric acute myeloid leukemia: a view from three tertiary centers in India" and "A model of BCR-FGFR1 driven human AML in immunocompromised mice."

The article presents information on various papers to be published in the fortcoming isssues of the periodical "British Journal of Haematology".

A list of papers to be published in forthcoming issues of the periodical related to several medical diseases including multiple myeloma, chronic lymphocytic leukemia and thrombocytosis is presented.

A list of papers to be published in forthcoming issues of the "British Journal of Haematology" is presented, including "Blood Donations: Justifying Blood Donor Restrictions," "What's in a Name? The Pharmacy of Vitamin K" and "ROR1-Based Immunomagnetic Protocol Allows Efficient Separation of CLL and Healthy B Cells."

In this issue, the British Society for Haematology presents guidelines for the diagnosis and management of patients with smouldering multiple myeloma (SMM). The authors provide a practical, evidence‐based approach to managing these patients. Key questions remain yet unsolved. Commentary on: Hughes et al. Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper. Br J Haematol 2024;204:1193‐1206. [ABSTRACT FROM AUTHOR]

In their paper, Hannan et al. suggest that new approaches to the management of the acute and remission phases of thrombotic thrombocytopenic purpura should be considered to address white matter changes seen in patients undergoing magnetic resonance imaging. Timely intervention may have significant implications for the long‐term physical and mental health of patients. Commentary on: Hannan et al. Cognitive decline in thrombotic thrombocytopenic purpura survivors: The role of white matter health as assessed by MRI. Br J Haematol 2024;204:1005‐1016. [ABSTRACT FROM AUTHOR]

Summary: Mesenchymal stromal cells (MSCs) are non‐haematopoietic cells found in fetal and adult organs, that play important roles in tissue repair, inflammation and immune modulation. MSCs residing in the bone marrow interact closely with haematopoietic cells and comprise an important component of the microenvironment supporting haematopoiesis, in both health and disease states. Since their identification in 1970, basic scientific and preclinical research efforts have shed light on the role of MSCs in the regulation of haematopoiesis and evoked interest in their clinical application in haematopoietic stem cell transplantation (HSCT) and malignant haematology. Over the last two decades, these research efforts have led to numerous clinical trials, which have established the safety of MSC therapy; however, the optimal mode of administration and the benefit remain inconclusive. In this paper, we will review the clinical experience with use of MSCs in HSCT for enhancement of engraftment, prevention and treatment of graft‐versus‐host disease and haemorrhagic cystitis. Then, we will discuss the contradictory evidence regarding tumour‐promoting versus tumour‐suppressing effects of MSCs in haematological malignancies, which may have relevance for future clinical applications. [ABSTRACT FROM AUTHOR]

Summary: Immune thrombocytopenia (ITP) may cause menstrual problems. This cross‐sectional study assessed menstrual problems in premenopausal chronic ITP women by several questionnaires, including the pictorial bleeding assessment calendar (PBAC; score ≥100 indicates heavy menstrual bleeding [HMB]), and the menorrhagia multiattribute scale (MMAS). Spearman was used for assessing correlations. A literature review was performed in Pubmed. The cohort comprised 37 women (mean age 31 ± 9). A total of 29/37 (78%) had experienced clinical menstrual problems in the present or past. Of the 33 patients who returned the PBAC, 13 (39%) had a score of ≥100. The median MMAS score was 79 (IQR 60–95). The PBAC scores correlated with the MMAS. Both questionnaires were unrelated to the platelet count. Patients with a levonorgestrel intrauterine device (LNG‐IUD) had lower PBAC scores than patients with other or no hormonal therapy. MMAS scores were correlated with fatigue. The review identified 14 papers. HMB occurred in 6%–55% at ITP diagnosis and 17%–79% during disease. Menstrual symptoms influenced the quality of life, particularly in patients with a low platelet count. This explorative study suggested that HMB is frequent in women with chronic ITP despite management and platelet counts >50 *109/l. An LNG‐IUD seemed to reduce blood loss significantly. [ABSTRACT FROM AUTHOR]

This includes recommendations on adjusting the haemostatic response for patients with postpartum haemorrhage, gastrointestinal haemorrhage, post-cardiac surgery, and older patients. In their paper Stanworth et al.1 present a comprehensive, updated guideline on the haematological management of major haemorrhage based on a systematic review of 96 articles published since 2015. The gastrointestinal haemorrhage trials excluded severe haemorrhages and these thresholds may not be appropriate for all gastrointestinal haemorrhages, let alone severe traumatic injury. Failure to rescue in geriatric trauma: the impact of any complication increases with age and injury severity in elderly trauma patients. [Extracted from the article]

A list of researches to be published in future issues of journal "British Journal of Haematology" is presented, which include "Low-dose pembrolizumab induced remission in patients with refractory classical Hodgkin lymphoma," and "A double centre retrospective study into rates of postpartum haemorrhage in women on low molecular weight heparin."

A list of articles to be published in an upcoming issue of the journal is presented, as of November 2016, including articles on topics like tumor related to hematological diseases, leukaemogenesis mechanisms, and mutations in paediatric acute myeloid leukaemia.

A list of articles to be published in the forthcoming issues of the "British Journal of Haematology" is presented including "Are myeloprolifetative neoplasms a risk factor for heparin-induced thrombocytopenia?," by J. Bover, "A mode of BCR-FGR1 driven human AML in immunicompromised mice," by J. Cowell and "Biopreservation of RBCs for in vitro Plasmodium falciparum culture," by M.M. Goheen.

A list of the articles to be published in upcoming issues of the "British Journal of Haematology" is presented.

The article presents information on papers to be published in forthcoming issues on topics including immunohematology, hematological oncology and internal medicine.

The article offers information on the paper to be published in the forthcoming issue of the periodical "British Journal of Haematology" on topics including cytoxity, ruxolitinib and calreticulin mutations.

In their paper the authors describe distinct transcriptomic changes associated to treatment response in core bone marrow biopsies from patients with acute myeloid leukaemia. This finding raises the possibility that stratifying patients for treatment according to their transcriptomic profiles could improve patients' response and prognosis. Commentary on: Treaba et al. Transcriptomics of AML core bone marrow biopsies reveals distinct therapy response‐specific osteo‐mesenchymal profiles. Br J Haematol 2023;200:740–754. [ABSTRACT FROM AUTHOR]

The article lists articles in forthcoming issues on topics including sickle cell disease, acute lymphoblastic leukaemia, and autoimmune diseases.

The article lists articles to be published in coming issues on topics including amyloidosis, splanchnic vein thrombosis, and multiple myeloma.

A list of the articles to be published in the "British Journal of Haematology" is presented including "Ruxolitinib Is an Effective Treatment for CALR-Positive Patients With Myelofibrosis," "Inspiration Amidst the Challenges: The First Report of Successful Bone Marrow Transplantation in the Himalayan Country Nepal," and "Disease-Free Survival Following High Dose or Standard Dose Therapy in Patients With Amyloidosis.

The article lists the studies to be published in forthcoming issues on topics including bowel perforation while on thalidomide treatment, imatinib treatment for leukemia patients, and ruxolitinib for myelofibrosis treatment.

The article lists the articles to be published in the May 2016 issue of "British Journal of Haematology" including "Heavy menstrual bleeding on rivaroxaban," "Monoclonal B cell Lymphocytosis and Hypogammaglobulinemia" and "Long non-coding RNAs: biomarkers for acute leukemia subtypes."